{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:35:42Z","timestamp":1780392942876,"version":"3.54.1"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":1678,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Use of telmisartan for the treatment of proteinuria in dogs has not been thoroughly investigated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis\/Objectives<\/jats:title>\n                    <jats:p>Telmisartan can be effective for the treatment of proteinuria in dogs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Forty-four client-owned dogs with proteinuria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective study. Dogs diagnosed with clinically relevant proteinuria (nonazotemic dogs with a urine protein-to-creatinine ratio [UPC] \u22652 and azotemic dogs with UPC \u22650.5) were separated into 3 groups: telmisartan alone, with benazepril, or with mycophenolate. The UPC was recorded before treatment and at subsequent follow-ups (1, 3, 6, and 12\u2009months, as available). Response to treatment was categorized as complete (UPC \u02c20.5), partial (UPC decreased by \u226550% but still \u22650.5), or no response (UPC decreased by &amp;lt;50%). Serum creatinine and potassium concentrations and arterial pressure also were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the telmisartan group, treatment response (UPC \u02c20.5 or decreased by \u226550%) was observed in 70%, 68%, 80%, and 60% of dogs at 1, 3, 6, and 12\u2009months follow-up, respectively. No significant changes were noted in serum creatinine or potassium concentrations, or in arterial blood pressure at all follow-up times. Adverse effects consisted of mild self-limiting gastrointestinal signs in 5 dogs. Two dogs developed clinically relevant azotemia that required discontinuation of the treatment before the first follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>Telmisartan can be considered for treatment of proteinuria in dogs, alone or in combination with other treatments for proteinuria.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.16146","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T08:59:58Z","timestamp":1620637198000},"page":"1810-1818","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Treatment of proteinuria in dogs with telmisartan: A\u00a0retrospective study"],"prefix":"10.1093","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7106-9134","authenticated-orcid":false,"given":"Julie","family":"Lecavalier","sequence":"first","affiliation":[{"name":"DMV Veterinary Center , Montr\u00e9al, Quebec,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyanne","family":"Fifle","sequence":"additional","affiliation":[{"name":"DMV Veterinary Center , Montr\u00e9al, Quebec,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Javard","sequence":"additional","affiliation":[{"name":"DMV Veterinary Center , Montr\u00e9al, Quebec,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,7,1]]},"reference":[{"key":"2026020922173457100_jvim16146-bib-0001","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1939-1676.2005.tb02713.x","article-title":"Assessment and management of proteinuria in dogs and cats: 2004 ACVIM Forum Consensus Statement (small animal)","volume":"19","author":"Lees","year":"2005","journal-title":"J Vet Intern Med"},{"issue":"4","key":"2026020922173457100_jvim16146-bib-0002","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cvsm.2010.09.006","article-title":"Protein-losing nephropathy in small animals","volume":"41","author":"Littman","year":"2011","journal-title":"Vet Clin North Am Small Anim Pract"},{"issue":"4","key":"2026020922173457100_jvim16146-bib-0003","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/vr.162.5.141","article-title":"Associations between proteinuria, systemic hypertension and glomerular filtration rate in dogs with renal and non-renal diseases","volume":"162","author":"Wehner","year":"2008","journal-title":"Vet Rec"},{"key":"2026020922173457100_jvim16146-bib-0004","article-title":"Ganong's Review of Medical Physiology","author":"Barrett","year":"2019","edition":"26"},{"key":"2026020922173457100_jvim16146-bib-0005","article-title":"Guyton and Hall Textbook of Medical Physiology","author":"Hall","year":"2016","edition":"13"},{"key":"2026020922173457100_jvim16146-bib-0006","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/jvim.15394","article-title":"Efficacy of long-term oral telmisartan treatment in cats with hypertension: results of a prospective European clinical trial","volume":"33","author":"Glaus","year":"2019","journal-title":"J Vet Intern Med"},{"key":"2026020922173457100_jvim16146-bib-0007","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.cvsm.2016.06.009","article-title":"Management of proteinuria in dogs and cats with chronic kidney disease","volume":"46","author":"Vaden","year":"2016","journal-title":"Vet Clin North Am Small Anim Pract"},{"issue":"4","key":"2026020922173457100_jvim16146-bib-0008","first-page":"631","article-title":"Proteinuria in dogs and cats","volume":"53","author":"Layenda","year":"2012","journal-title":"Can Vet J"},{"key":"2026020922173457100_jvim16146-bib-0009","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1111\/jvim.12230","article-title":"Consensus recommendations for standard therapy of glomerular disease in dogs","volume":"27","author":"Brown","year":"2013","journal-title":"J Vet Intern Med"},{"key":"2026020922173457100_jvim16146-bib-0010","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1939-1676.2000.tb02271.x","article-title":"Effects of enalapril versus placebo as a treatment for canine idiopathic glomerulonephritis","volume":"14","author":"Grauer","year":"2000","journal-title":"J Vet Intern Med"},{"key":"2026020922173457100_jvim16146-bib-0011","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1111\/jvim.15331","article-title":"ACVIM consensus statement: guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats","volume":"32","author":"Acierno","year":"2018","journal-title":"J Vet Intern Med"},{"issue":"4","key":"2026020922173457100_jvim16146-bib-0012","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/1098612X18761439","article-title":"Evaluation of orally administered telmisartan for the reduction of indirect systolic arterial blood pressure in awake, clinically normal cats","volume":"21","author":"Coleman","year":"2019","journal-title":"J Feline Med Surg"},{"issue":"4","key":"2026020922173457100_jvim16146-bib-0013","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0022-3565(25)38613-1","article-title":"The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (DuP753\/MK954) in the dog","volume":"268","author":"Christ","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"2026020922173457100_jvim16146-bib-0014","first-page":"460","article-title":"Saunders Handbook of Veterinary Drugs, Small and Large Animal","author":"Papich","year":"2016","edition":"4"},{"issue":"4","key":"2026020922173457100_jvim16146-bib-0015","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1161\/01.HYP.35.1.155","article-title":"Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function","volume":"35","author":"Carey","year":"2000","journal-title":"Hypertension"},{"issue":"4","key":"2026020922173457100_jvim16146-bib-0016","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.ijcard.2012.04.058","article-title":"Effects of telmisartan on proteinuria or albuminuria: a meta-analysis of randomized trials","volume":"167","author":"Takagi","year":"2013","journal-title":"Int J Cardiol"},{"key":"2026020922173457100_jvim16146-bib-0017","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1111\/jvim.12471","article-title":"Telmisartan treatment of refractory proteinuria in a dog","volume":"28","author":"Bugbee","year":"2014","journal-title":"J Vet Intern Med"},{"issue":"4","key":"2026020922173457100_jvim16146-bib-0018","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1111\/jvim.15958","article-title":"Efficacy of telmisartan for the treatment of persistent renal proteinuria in dogs: a double-masked, randomized clinical trial","volume":"34","author":"Louren\u00e7o","year":"2020","journal-title":"J Vet Intern Med"},{"key":"2026020922173457100_jvim16146-bib-0019","article-title":"Plumb's Veterinary Drug Handbook","author":"Plumb","year":"2018","edition":"9"},{"key":"2026020922173457100_jvim16146-bib-0020","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/jvim.13639","article-title":"Comparison of efficacy of long-term oral treatment with telmisartan and benazepril in cats with chronic kidney disease","volume":"29","author":"Sent","year":"2015","journal-title":"J Vet Intern Med"},{"key":"2026020922173457100_jvim16146-bib-0021","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/ki.2008.204","article-title":"Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy","volume":"74","author":"Bakris","year":"2008","journal-title":"Kidney Int"},{"key":"2026020922173457100_jvim16146-bib-0022","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.2215\/CJN.03250807","article-title":"Slowing nephropathy progression: focus on proteinuria reduction","volume":"3","author":"Bakris","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"2026020922173457100_jvim16146-bib-0023","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/eurheartj\/16.suppl_N.103","article-title":"Aldosterone escape during ACE inhibition therapy in chronic heart failure","volume":"16","author":"Struthers","year":"1995","journal-title":"Eur Heart J"},{"key":"2026020922173457100_jvim16146-bib-0024","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s11886-000-0077-3","article-title":"Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure","volume":"2","author":"Ennezat","year":"2000","journal-title":"Curr Cardiol Rep"},{"key":"2026020922173457100_jvim16146-bib-0025","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.2215\/CJN.03270807","article-title":"Are two better than one? Angiotensin-converting enzyme inhibitors plus angiotensin receptor blockers for reducing blood pressure and proteinuria in kidney disease","volume":"3","author":"Linas","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026020922173457100_jvim16146-bib-0026","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1523-1755.2005.00145.x","article-title":"Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications","volume":"67","author":"Wolf","year":"2005","journal-title":"Kidney Int"},{"issue":"4","key":"2026020922173457100_jvim16146-bib-0027","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3109\/0886022X.2015.1012995","article-title":"Meta-analysis: the efficacy and safety of combined treatment with ARB and ACEI on diabetic nephropathy","volume":"37","author":"Ren","year":"2015","journal-title":"Ren Fail"},{"issue":"4","key":"2026020922173457100_jvim16146-bib-0028","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nrcardio.2013.28","article-title":"Pharmacotherapy: optimal blockade of the renin-angiotensin-aldosterone system","volume":"10","author":"Nussberger","year":"2013","journal-title":"Nat Rev Cardiol"},{"key":"2026020922173457100_jvim16146-bib-0029","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.pop.2014.08.002","article-title":"Renin-angiotensin-aldosterone system inhibition","volume":"41","author":"Mercier","year":"2014","journal-title":"Prim Care"},{"key":"2026020922173457100_jvim16146-bib-0030","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1001\/archinte.167.18.1930","article-title":"Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials","volume":"167","author":"Phillips","year":"2007","journal-title":"Arch Intern Med"},{"key":"2026020922173457100_jvim16146-bib-0031","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/ijcp.12803","article-title":"Calibrating the impact of dual RAAS blockade on the heart and the kidney\u2014balancing risks and benefits","volume":"70","author":"Ziff","year":"2016","journal-title":"Int J Clin Pract"},{"key":"2026020922173457100_jvim16146-bib-0032","article-title":"Textbook of Veterinary Internal Medicine","author":"Ettinger","year":"2017","edition":"8"},{"key":"2026020922173457100_jvim16146-bib-0033","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1111\/jvim.15837","article-title":"Clinicopathologic characteristics, pathology, and prognosis of 77 dogs with focal segmental glomerulosclerosis","volume":"34","author":"Lorbach","year":"2020","journal-title":"J Vet Intern Med"},{"key":"2026020922173457100_jvim16146-bib-0034","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1111\/jvim.12228","article-title":"Consensus recommendations for immunosuppressive treatment of dogs with glomerular disease based on established pathology","volume":"27","author":"Segev","year":"2013","journal-title":"J Vet Intern Med"},{"key":"2026020922173457100_jvim16146-bib-0035","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1111\/jvim.12222","article-title":"Consensus guidelines for immunosuppressive treatment of dogs with glomerular disease absent a pathologic diagnosis","volume":"27","author":"Pressler","year":"2013","journal-title":"J Vet Intern Med"},{"key":"2026020922173457100_jvim16146-bib-0036","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1111\/jvim.12247","article-title":"Prevalence of immune-complex glomerulonephritis in dogs biopsied for suspected glomerular disease: 501 cases (2007-2012)","volume":"27","author":"Schneider","year":"2016","journal-title":"J Vet Intern Med"},{"key":"2026020922173457100_jvim16146-bib-0037","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/jvim.13832","article-title":"Correlation of urine and serum biomarkers with renal damage and survival in dogs with naturally occurring proteinuric chronic kidney disease","volume":"30","author":"Hokamp","year":"2016","journal-title":"J Vet Intern Med"},{"key":"2026020922173457100_jvim16146-bib-0038","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ihj.2016.08.007","article-title":"Angiotensin-converting enzyme inhibitors and receptor blockers in heart failure and chronic kidney disease- demystifying controversies","volume":"69","author":"Muneer","year":"2017","journal-title":"Indian Heart J"},{"key":"2026020922173457100_jvim16146-bib-0039","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.kint.2016.09.038","article-title":"Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes","volume":"91","author":"Clase","year":"2017","journal-title":"Kidney Int"},{"key":"2026020922173457100_jvim16146-bib-0040","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1111\/j.1755-5922.2010.00258.x","article-title":"Hyperkalemia associated with use of angiotensin-converting enzyme inhibitor and angiotensin receptor blockers","volume":"30","author":"Raebel","year":"2012","journal-title":"Cardiovasc Ther"},{"issue":"4","key":"2026020922173457100_jvim16146-bib-0041","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1111\/j.1523-1755.2000.00381.x","article-title":"ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group","volume":"58","author":"Bakris","year":"2000","journal-title":"Kidney Int"},{"key":"2026020922173457100_jvim16146-bib-0042","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.2165\/00003495-200161100-00009","article-title":"Telmisartan","volume":"61","author":"Sharpe","year":"2001","journal-title":"Drugs"},{"key":"2026020922173457100_jvim16146-bib-0043","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/jvim.14872","article-title":"Comparison of single, averaged and pooled urine protein: creatinine ratios in proteinuric dogs undergoing medical treatment","volume":"32","author":"Shropshire","year":"2018","journal-title":"J Vet Intern Med"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvim.16146","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvim.16146","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/35\/4\/1810\/66651864\/jvim16146.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/35\/4\/1810\/66651864\/jvim16146.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T03:28:13Z","timestamp":1770694093000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/35\/4\/1810\/8446959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,1]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.16146","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7]]},"published":{"date-parts":[[2021,7,1]]},"assertion":[{"value":"2020-12-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}